2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
104
Neoplasms
11
Neoplasm Metastasis
11
Glioma
8
Ovarian Neoplasms
6
Melanoma
6
Glioblastoma
6
Squamous Cell Carcinoma of Head and Neck
5
Liposarcoma
5
Carcinoma, Non-Small-Cell Lung
5
Sarcoma
4
Recurrence
4
Medulloblastoma
4
Endometrial Neoplasms
4
Diffuse Intrinsic Pontine Glioma
4
Colorectal Neoplasms
4
Breast Diseases
4
Brain Neoplasms
4
Neuroblastoma
3
Neoplasms by Site
3
Lymphoma
3
Hereditary Sensory and Autonomic Neuropathies
3
Fallopian Tube Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Breast Neoplasms, Male
3
Astrocytoma
3
Triple Negative Breast Neoplasms
2
Rhabdoid Tumor
2
Prostatic Neoplasms
2
Neoplasms, Germ Cell and Embryonal
2
Interventions
Cyclophosphamide
87
fludarabine
77
fludarabine phosphate
45
Tacrolimus
45
Whole-Body Irradiation
42
Mycophenolic Acid
42
Busulfan
35
Melphalan
32
Antilymphocyte Serum
24
Methotrexate
23
thymoglobulin
22
Standard of Care
22
Rituximab
22
Thiotepa
20
Sirolimus
20
Azacitidine
20
venetoclax
19
Stem Cell Transplantation
18
Granulocyte Colony-Stimulating Factor
18
Practice Guidelines as Topic
17
Cytarabine
16
Bortezomib
16
Nivolumab
15
Filgrastim
15
Specimen Handling
14
Dexamethasone
14
Blood Specimen Collection
14
Cyclosporine
13
Surveys and Questionnaires
12
Mesna
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
ribociclib
×
Clear all
NCT02187783
2019-07-18
SIGNATURE
Novartis
Phase 2
Completed
106 enrolled
16 charts